Vivos Therapeutics (VVOS) Projected to Release Quarterly Earnings on Tuesday

Vivos Therapeutics (NASDAQ:VVOS) is projected to post its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect the company to post earnings of ($0.42) per share and revenue of $5.6330 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 5:00 PM ET.

Vivos Therapeutics (NASDAQ:VVOS) last issued its earnings results on Wednesday, May 20th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.07). The business had revenue of $5.14 million for the quarter, compared to analyst estimates of $4.35 million. Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 127.70%. On average, analysts expect Vivos Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vivos Therapeutics Stock Performance

NASDAQ VVOS opened at $0.32 on Tuesday. Vivos Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $5.12. The firm’s fifty day moving average price is $0.48 and its two-hundred day moving average price is $0.95. The stock has a market cap of $4.42 million, a PE ratio of -0.15 and a beta of 6.22.

Institutional Trading of Vivos Therapeutics

Several large investors have recently made changes to their positions in the company. XTX Topco Ltd bought a new stake in Vivos Therapeutics in the 2nd quarter valued at about $65,000. B. Riley Wealth Advisors Inc. bought a new position in Vivos Therapeutics in the second quarter worth approximately $220,000. DRW Securities LLC boosted its holdings in Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after acquiring an additional 74,441 shares in the last quarter. Finally, Connective Capital Management LLC acquired a new stake in Vivos Therapeutics in the third quarter valued at approximately $620,000. 26.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on VVOS shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Friday, July 17th. HC Wainwright cut their price target on shares of Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a report on Friday, April 17th. Finally, Ascendiant Capital Markets raised their target price on Vivos Therapeutics from $3.00 to $3.10 and gave the stock a “buy” rating in a research report on Thursday, June 4th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Vivos Therapeutics presently has a consensus rating of “Hold” and an average price target of $2.80.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.